BTIG Downgrades Foghorn Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 89.3%

Neg 89.3% Neu 0% Pos 0%

BTIG analyst Jeet Mukherjee downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Neutral.

Comments

No comments yet. Be the first!